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KESAN l-KEPTUHANr PRESKRIBER KEPADA KONSENSUS MALAYSIA 
BAGJ--pENGURUSAN DIABETES MELLITUS JENIS-2 UNTUK 
PESAKIT YANG DIMASUKKAN KE HOSPITAL 
PULAU PINANG DAN PENGURUSAN DIRI 
ABSTRAK 
Diabetes mellitus ialah penyakit tak menular yang paling biasa ditemui di merata dunia 
yang dikaitkan dengan pelbagai komplikasi serius. Pengurusan yang betul akan dapat 
menangguhkan perkembangan komplilkasinya. Banyak negara telah menerbitkan 
panduan amalan bagi pengurusan diabetes untuk membantu pakar perubatan 
memberikan penjagarui yang terbaik bagi pesakit- pesakit diabetes. Kajian ini bertujuan 
untuk menilai pematuhan para preskriber terhadap pengurusan panduan amalan klinikal 
bagi Diabetes Mellitus Jenis ke 2 (T2DM) (the Malaysian Consensus MC, 1996) bagi 
pesakit-pesakit dewasa T2DM yang dimasukkan ke Hospital Pulau Pinang (HPP) 
kerana belum ada kajian yang meniliti kepatuhan ini di Malaysia. Di samping itu ia 
bertujuan untuk menilai pengetahuan umum tentang pesakit-pesakit T2DM dari segi 
swarawatan penyakit mereka. Pengumpulan data prospektif telah dijalankan bersama-
sama dengan sesi temuduga pesakit dan kajian retrospektif. Pendekatan "dari bawah ke 
atas". telah digunakan bagi menganggar kos perubatan langsung dan kos tempoh rawatan 
di hospital bagi setiap pesakit. Natijahnya kepada pesakit dan kosnya dinilai dan 
dianalisa bagi kesemua subjek dan dibandingkan dengan pematuhan dengan 
garispanduan MC. Daripada maklumat kseluruhan 154 pesakit, 46.8% terdiri daripada 
XXV 
lelaki, 53.2% wanita dan majoriti pesakit (55.8%) tidak obes. Diabetes yang tak terkawal 
digambarkan dalam bentuk hipoglisemia-(39.0%) atau hiperglisemia (33.7%) merupakan 
sebab paling biasa pesakit dimasukkan ke hospital, manakala hipertensi (HPT) 
merupakan komorbiditi yang pradominan (66.2). Lima puluh dua pesakit (33.8%) 
dianggap pesakit yang barn dikesan kerana mereka baru dikesan mengalami diabetes 
dalam tempoh beberapa hari sehingga ~ 3 tahun. Pesakit yang bakinya, 66.2% telah 
dikesan dalam tempoh 3 sehingga ~ 10 tahun daripada tarikh panduan MC dikeluarkan 
sehingga tempoh pengumpulan data. Daripada pesakit- pesakit ini, 50 orang telah 
dirawat dengan mematuhi garispanduan MC, manakala 104 orang pesakit lagi diurus 
dengan cara tidak mematuhi garispanduan MC. Bilangan dan kekerapan pengubatan 
yang ditetapkan adalah lebih tinggi dalam kalangan kumpulan yang tak patuh, namun 
perbezaannya tidak signifikan secara statistic (nilai P > 0.05). Merskipun tidak ada 
perbezaari signifikan dalam BG purata semasa dimasukkan ke hospital dan semasa 
dibenarkan pulang pada kedua-dua kumpulan tersebut, bilangan pesakit yang 
mempunyai tahap BG yang baik semasa dibenarkan pulang lebih tinggi dalam kalangan 
kumpulan yang patuh. Purata jumlah kos rawatan hospital dalam kalangan kumpulan 
yang tak patuh didapati jauh lebih tinggi (RM 643.09) berbanding dengan kumpulan 
yang patuh (RM 593.62). Kajian ini mendapati majoriti preskriber tidak patuh dengan 
panduan MC untuk mengurus pesakit-pesakit T2DM di HPP. Walaupun keputusan 
menunjukkan tidak ada perbezaan signifikan di antara kumpulan yang dirawat dengan 
patuh dan yang tak patuh, kumpulan yang patuh mengalami pembaikan yang lebih baik 
xxvi 
dalam kawalan glisemia dan juga kos purata rawatan hospital yang lebih rendah. Kohort 
temuduga pula menunjukkan mereka kekurangan pengetahuan tentang pengurusan 
diabetes dan terlalu sedikit daripada mereka yang didapati mematuhi program penjagaan 
diri yang dicadangkan. 
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THE IMPACT OF COMPLIANCE OF THE PRESCRIBERS TO 
THE MALAYSIAN CONSENSUS FOR TYPE 2 DIABETES 
MELLITUS MANAGEMENT FOR HOSPITALIZED 
PENANG HOSPITAL'S PATIENTS AND 
THEIR SELF MANAGEMENT 
ABSTRACT 
Diabetes mellitus, (DM) is the most common non-communicable disease worldwide which 
is associated with various serious complications. Proper management delays the 
development of complications. Various countries have developed practice guidelines for 
the management of diabetes to assist physicians in providing the best care for diabetic 
patients. This study was aimed to evaluate the prescribers' compliance with the clinical 
practice guideline for Type 2 Diabetes Mellitus (T2DM) management (the Malaysian 
Consensus MC, 1996) for adult T2DM patients admitted to Hospital Pulau Pinang (HPP), 
because there was no previous studies investigated the compliance in to the MC in 
Malaysia and to assess the general knowledge of T2DM patients regarding self-
management of their disease. A prospective data collection was carried out in combination 
with patient interviews and retrospective study. The "bottom up" approach was used to 
estimate the direct medical costs and average hospitalization cost per patient stay. 
Patients' outcomes and costs were evaluated and analyzed for the whole subjects and in 
comparison to compliance with the MC. Of these 154 patients, 46.8% were male, 53.2% 
were female and the majority of patients (55.8%) were not obese. Uncontrolled diabetes 
xxviii 
manifesting as hypoglycaemia (39.0%) or hyperglycaemia (33.7%) were the most common 
causes of admission, whereas hypertens-ion (HPT) was the predominant co-morbidity 
(66.2%). Fifty two (33.8%) patients were considered newly diagnosed, as they had been 
diagnosed with diabetes within days to :S 3 years. The remaining 66.2% patients had been 
diagnosed for 3 up to ~ 10 years, from the MC issued until the data collection period. Of 
these patients, 50 were treated in compliance with the MC guidelines, whereas 104 patients 
were managed in a manner that was not compliant with the MC. The number and 
frequency of prescribed medications was higher among the non-compliance group, but the 
difference did not attain statistical significance (P value > 0.05). Although there was no 
significant difference in the average BG during hospitalization and upon discharge 
~!' 
between the two groups, the number of patients with a good BG level at discharge was 
higher in the compliance group. The average total cost of hospitalization for the non-
compliant group was considerably higher (RM 643.09) than the compliant group (RM 
593.62). This study found that majority of the prescribers did not comply with the MC for 
the management of T2DM patients at HPP. Although the results showed non-significant 
differences between the compliant and non-compliant treated groups, the compliant group 
experienced better improvements in glycaemic control as well as a lower average cost of 
hospitalisation. Patient interviews of the cohort revealed that, there was a lack of general 
knowledge about diabetes management and minimal adherence to the recommended self-
care program was also observed in this cohort. 
xxix 
1.1 Background 
CHAPTER ONE 
INTRODUCTION 
Diabetes is a general name for the illness characterised by an excessive excretion of urine 
(polyuria). The word "diabetes" was derived from a Greek word "diabainein" which 
means "to siphon" or "to pass through" (http://www.whtbhc.com/diabetesD. Diabetes 
also means "the legs are spreading" (due to the strengthened urine), which refers to the 
increase in the frequency of urination. The word "Mellitus" comes from the Latin word 
"mellitus", which means "honey sweet". Thus the name "diabetes mellitus", or "honey 
sweet flow" refers to the sweet taste of patient's urine and blood 
(http:/ /www.blurtit.com/q526150.html). 
There are two main diabetic conditions: diabetes mellitus and diabetes insipidus. Both 
are associated with incr~ased thirst and an increased production of urine. Diabetes 
insipidus is a disease caused by decreased production, secretion or function of the anti-
diuretic hormone (ADH), which leads to excessive loss of water from the kidney. The 
term "diabetes insipidus" refers to the quantity and quality of the urine (Corwin, 2000). 
In the past, these two types of diabetes were distinguished by tasting patient urine: in the 
case of diabetes mellitus, the urine has a relatively sweet taste due to its sugar content, 
while in the case of diabetes insipidus the urine has a dilute and watery taste or "copious 
amount" of dull, or tasteless urine (Roberts, 1866). In this thesis, the word diabetes 
always refers to diabetes mellitus. 
1 
1.1.1 Definition 
Diabetic mellitus (DM) is a group of metabolic disorders characterised by 
hyperglycaemia due to a relative or absolute lack of insulin, or cellular insensitivity to 
insulin (American Diabetes Association· (ADA), 2007). DM is characterized by 
abnormalities in carbohydrate, fat and protein metabolism. In the long term, DM results 
in chronic complications including micro-vascular, macrovascular and neuropathic 
changes that manifest in organ damage. If not effectively treated DM in its most acute 
and severe form can lead to confusion, loss of consciousness and death (Mealey and 
Ocampo, 2007). 
1.1.2 Diabetes Mellitus Classification 
A 1999 report from the World Health Organization (WHO) classified DM and other 
categories of hyperglycaemia according to their various clinical stages and aetiological 
types. As well as, the American Diabetes Association (ADA), (2005), categorised DM 
into four different classes according to its clinical and aetiological characteristics. 
1.1.2 (a) Type 1 DM 
Type 1 DM (T1DM) is often referred to as immune-mediated, insulin-dependent, or 
juvenile onset diabetes. It accounts for only 5-l 0% of diabetes cases (Daneman, 2006). 
TIDM results from the destruction of the ~-cells of the pancreas, which drastically 
lowers or eliminates the secretion of insulin. 
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1.1.2 (b) Type 2 DM 
Type 2 DM (T2DM) is the most common form ofDM, and accounts for 90-95% ofthose 
with diabetes (Broadhurst and Domenico, 2006)0 It is also referred to as non-insulin 
dependent (NIDDM) or adult onset diabet~s. T2DM can affect individuals of any age; 
even children may be diagnosed with T2DM (Pinhas-Hamiel and Zeitler, 2005). 
Hyperglycaemia, insulin resistance and a relative impairment of insulin secretion are the 
hallmarks of this condition. 
1.1.2 (c) Gestational DM 
Gestational DM (GDM) is a condition of glucose intolerance resulting in hyperglycaemia 
of variable severity with onset or first recognition during pregnancy. It occurs normally 
in the third trimester of pregnancy (Buchanan and Xiang, 2005), and women with GDM 
are at high risk for developing diabetes. 
1.1.2 (d) Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) 
The IGT and/or IFG are known as "pre-diabetes", which is an intermediate condition of 
high blood glucose levels that does not meet the specific criteria for a diagnosis of 
diabetes, but is a risk factor for diabetes and cardiovascular disease (V alensi et al., 2005). 
A patient with IGT and IFG has a higher chance of developing DM in the later stages of 
their life. 
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1.1.2 (e) Other specific types ofDM 
This category includes the less common causes of DM, such as several conditions 
associated with monogenetic defects in ~-cell function (ADA, 2007). It includes diabetes 
caused by a specific and identified underlying defect, such as genetic defects of ~-cell 
<:! 
function, genetic defects in insulin action, diseases of the exocrine pancreas, 
endocrinopathies and drug or chemical induced disease. These types of DM are 
characterized by early onset of hyperglycaemia (before age of 25 years). They are 
referred to as maturity onset diabetes of the young (MODY), and are characterized by 
impaired insulin secretion with minimal or no defects in insulin action. 
1.1.3 Pathophysiology 
DM is a disease of hyperglycaemia, which is defined as a blood glucose level higher than 
normal. Hyperglycaemia is usually caused by an insulin deficiency, such as in TIDM, or 
as a result of decreased cellular responsiveness to insulin, such as in T2DM. (Corwin 
2000). 
1.1.3 (a) Pathogenesis 
The autoimmune destruction of the insulin producing P-cells in the pancreatic islets of 
Langerhans leads to loss of insulin secretion (Rabinovitch and Suarez-Pinzon, 1998). 
This destruction may be due to environmental factors such as viruses or toxins, or genetic 
factors (Lefebvre et a!., 2006). The resulting absolute insulin deficiency is characteristic 
ofTlDM. 
4 
Impaired insulin secretion and/or resistance to insulin action characterises T2DM. This 
insulin resistance decreases tissue uptake of glucose, causing an excessive accumulation 
of glucose in the circulation, which known as hyperglycaemia (Goldstein, 2003). This 
hyperglycaemia stimulates the pancreas to produce more insulin in an attempt to 
overcome insulin resistance. If pancreatic insulin secretion is not sufficient for the 
metabolic needs of the body, the final consequence is uncontrolled hyperglycaemia. 
Patients with T2DM exhibit various degrees of tissue resistance to insulin, impaired 
insulin secretion and increased basal hepatic glucose production. Persistent or prolonged 
hyperglycaemia is associated with multiple disorders including obesity, atherosclerosis, 
hyperlipidaemia, hypertension, renal failure, blindness and other cardiovascular diseases 
{Golden et al., 2007). The specific causes of T2DM are unknown; however, there does 
seem to be a genetic component as patients with T2DM have been shown to have a 
stronger family history of diabetes compared with TIDM patients (Koda Kimble, et al., 
2001; Katz and Abraham, 2006; Linn, eta!, 2008). 
1.1.3 (b) Signs and symptoms 
Each type of diabetes presents differently. TIDM, which develops due to damage of 
insulin-producing P.islet cells in the pancreas, presents most -commonly at a younger age. 
TlDM patients are likely to have hyperglycaemia, develop serum ketoacidosis and 
require exogenous insulin for blood glucose control (McAnulty, et al., 2000). On the 
other hand, T2DM develops only when insulin is either dysfunction or inadequate. It 
may develop at any age, although it is usually develops in adults. Although T2DM is 
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usually associated with obese patients, it may also affect non-obese people (Fujita et a!., 
2009). T2DM can be treated with oral agents, and ketoacidosis is uncommon, therefore 
exogenous insulin is not essential for its treatment. 
Both Tl DM and T2DM present with similar symptoms, such as increased thirst with 
frequent urination, unexpected weight loss, weakness and fatigue, extreme hunger and 
blurred vision. Other symptoms of T2DM include an increased frequency of infections 
and cuts, or bruises that do not heal quickly (Berl et al., 2007). In the early stages, 
T2DM may not exhibit any signs or symptoms, or they may be so mild that they go 
unnoticed. Compared to TlDM, the evident symptoms of T2DM take a much longer 
time to develop http://www.iohnshopkinshohealthallert.com). Although majority cases 
of T2DM may experience the symptoms of DM, patients are often not aware that their 
symptoms are related to DM, and they may avoid seeing their medical practitioner 
(Preshaw, 2008). Very often patients are not aware that they have T2DM until they have 
developed its complications, such as blurry vision or chest pain as a warning sign of 
ischemia. In 2007, Unger found that many macrovascular and microvascular 
complications may be noticeable on first diagnosis due the slowly progressive nature of 
T2DM and the development of chronic hyperglycaemia. Unfortunately, oral 
pharmacologic therapies are becoming less effective for minimizing the effects of 
chronic hyperglycaemia due to the deterioration of p-cell function and serious insulin 
resistance over time. 
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1.1.4 General complications 
DM, if left untreated, can result in various complications. Excessive circulating blood 
glucose may cause damage to nerves and blood vessels. Blood vessel damage may be 
both macro- and microvascular, and can· cause damage to multiple organs (Pessina, 
2007). The microvascular complications of DM include neuropathy, nephropathy, and 
retinopathy. The macrovascular complications of DM may lead to the development of 
various cardiovascular diseases (CVDs), such as hypertension, ischemic heart disease, 
acute myocardial infarction and heart failure. In addition, DM is also one of the main 
causes of stroke in the United States according to the U.S. National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK, 2004). 
1.1.4 (a) Cardiovascular disease - heart disease and increased risk of stroke 
Macrovascular complications, such as CHD, stroke and peripheral vascular disease 
usually occur at a younger age in the majority of diabetic patients, (Koda Kimble et al., 
2001). Winer and Sowers reported in 2002 that the risk of developing CVD is higher in 
diabetic patients compared with non-diabetic patients in the general population. 
Cardiovascular diseases (CVDs) are the main cause of diabetes related death, 
contributing to 65% of all diabetes mortality (Grundy et al., 1999). At present, diabetes 
is considered the main risk factor for several forms of CVD since approximately 75 to 
· 80% of all diabetic patients develop a severe form of those complications, (Koda Kimble 
et al., 2001). The incidence of CHD and myocardial infarction (MI) are about two to 
three times higher in diabetic than non-diabetic patients. Of all prematoce deaths in 
diabetic patients from CHD, 50% were squeal of T2DM. The CVD risk in diabetic 
7 
patients is aggravated by the presence of other co-morbidities such as smoking, 
hypertension, high serum cholesterol and obesity (Solano and Goldberg, 2005). 
1.1.4 (b) Neuropathy 
Diabetic neuropathy (DN) ts heterogeneous collection of nerve damage conditions 
caused by uncontrolled BG. They are a consequence of metabolic disturbances in the 
neurons, microangiopathy affecting the capillary supply to neurons, or an autoimmune 
process (Koda Kimble eta!., 2001). Neuropathy most commonly presents as a diffuse, 
symmetric sensorimotor syndrome such as carpal tunnel syndrome or as autonomic 
neuropathy. In 2008, The U.S. National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) demonstrated that DN occurs as a consequence of decreased blood 
flow and high blood sugar (BS) levels; hence, diabetic patients with uncontrolled blood 
sugar levels have a higher incidence of this complication. About 60-70% of diabetic 
patients have some form of neuropathy, and the risk of experiencing this complication 
increases with age and duration of diabetes. However, Vinik and Mahayana reported in 
2004 that the true prevalence of DN is not known. Various reports suggest that DN is 
present in I 0% to 90% of diabetic patients, depending on the criteria and methods used 
to define neuropathy. 
Autonomic neuropathy is defined as the diabetes-related damage caused to the nerves 
that control the bladder, digestive tract and reproductive organs. The 2007 National 
Diabetes Fact Sheet reported that about two-thirds of diabetic patients are susceptible to 
have mild to severe forms of autonomic nervous system damage such as impaired 
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sensation or pain in the feet or hands, decreased rate of digestion of food in the stomach, 
carpal tunnel syndrome, erectile dysfunction, or other forms of nerve problems. 
Peripheral neuropathy affects the nerves controlling the extremities, especially the feet 
and legs. Numbness and tingling, sensitivity to touch or muscle weakness are signs of 
such a neuropathy (Vinik and Mahayana, 2004; Diabetes UK, 2008). About one third of 
diabetic patients aged 40 years or older have impaired sensation or a total lack of feeling 
in their feet. This decreased sensation can contribute to foot injuries and infections, 
which can develop into foot ulcers, as patients are unable to feel them. These foot ulcers 
are the major contributing cause of lower-limb amputations in diabetic· patients 
(Apostolou and Ram, 1999; Illa, 1999). 
1.1.4 (c) Nephropathy- kidney damage and kidney failure 
Prolonged elevation ofBS levels will also affect the microvasculature ofthe kidney, thus 
interfering in its normal filtration function. This deterioration is known as kidney disease 
of diabetes, or diabetic nephropathy (Christensen, 2004). Diabetic nephropathy develops 
in both TIDM and T2DM patients. T2DM is the more common cause of End-Stage 
Renal Disease (ESRD), and approximately 40% of all T2DM patients develop diabetic 
nephropathy (Tourah, 2008). This prevalence is expected to increase significantly world-
wide due to the epidemic-like expansion of number of T2DM cases (Rossing et al., 
2004). Diabetic nephropathy is characterised by continual albuminuria, elevated blood 
pressure and a progressive decline in kidney function, which eventually leads to ESRD. 
Deteriorations in renal function also exacerbate any existing cardiovascular disease, 
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which can further aggravate renal failure. Kidney damage and the development of end-
stage renal disease usually take years to develop (Kidney failure), (International Diabetes 
Federation (IDF), 2003). 
1.1.4 (d) Retinopathy - vision problems and blindness 
Diabetic retinopathies are DM related complications that are characterised by progressive 
microvascular complications including micro-aneurysms, which are swellings and 
blockages of the vessels supplying the retina. As the number of blocked blood vessels 
increase, a condition known as severe non-proliferative retinopathy develops (Leiter, 
2005). In 2006 and 2008 studies, the U.S. National Eye Institute reported that the growth 
of new abnormal and fragile vessels (proliferative retinopathy) occurs at a more 
advanced disease stage, and when these vessels leak, severe vision loss and blindness can 
occur. A Florida study by Chalam et al., in 2005 found that about 25-80% of TIDM 
patients develop retinopathy within five to fifteen years after diagnosis. This rate of 
incidence is higher in T2DM patients nineteen years after diagnosis, but varies between 
patients who are taking insulin (40-84%) and those who are only on oral hypoglycaemics 
(24-53%). Furthermore, 2007 National Diabetes Statistics reported that diabetes is the 
leading cause of new cases of blindness among adults aged 20 to 74 years in the US. 
1.2 Epidemiology 
1.2.1 World wide prevalence 
The prevalence of diabetes mellitus (DM) is increasing throughout the world due to 
aging, accelerated population growth, urbanisation, the high prevalence of obesity and 
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inactive lifestyles. In 2007, Herman illustrated that the prevalence of DM increases 
considerably over time nationwide, and that it is one of the main causes of morbidity and 
mortality worldwide. This study also found a significant difference in the prevalence of 
DM among different racial and ethnic groups. Abate and Chandalia (2003) found 
important differences in the incidence of DM and its complications between countries as 
well as between ethnic, cultural and even age groups within the same country. 
Although diabetes has been recognized clinically for thousands of years, rigorous 
scientific study of its epidemiology has only been conducted within the past several 
decades. The WHO Global Burden of Disease Report estimated that there were over 177 
million adults worldwide suffering from diabetes in 2002. About two thirds of these 
people were reported to live in developing countries (WHO, 2003). 
The prevalence ofDM in the United States continues to increase, with a staggering toll in 
acute and chronic complications, as well as disability and death. Diabetes is the sixth 
most common cause of death in the US (Steinbrook, 2006). The Centre for Disease 
Control and Prevention estimated in 2005 that 20.8 million persons in the USA, 
representing about 7% of the population, had diabetes. This estimate may only represent 
about two thirds of diagnosed diabetic patients in the USA, as many cases have never 
been diagnosed (Ekoe et al., 2001). The incidence of diabetes is expected to double by 
the year 2030. In 2004, Segal and Karen reported that T2DM had become one of the 
most serious health concerns in the U.S., affecting an estimated 18.2 million Americans. 
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The prevalence of DM is increasing, particularly among youth and young adults, in 
parallel with the continuing rise in obesity. 
Studies in 2003 by Aguilar-Salinas et al., were reported similar trends for DM in Mexico. 
Over the past 30 years, diabetes has become a public health problem in Mexico with 
considerable medical, social and economic consequences. The mortality rate due to 
diabetes has increased gradually since 1940s. Over the past 40 years, diabetes has risen 
to become the fourth leading cause of death in Mexico, after cardiovascular problems, 
neoplastic diseases and accidents and violence (Ekoe eta!., 2001). 
An epidemiological review and study of DM in Europe conducted by in 2000 by Ozturk 
et al., reported that DM affected 30 million people out of the entire European population 
of 850 million people, including Turkey. Out of these, four million had a diagnosis of 
insulin-dependent diabetes mellitus (IDDM) and 26 million were suffering from non-
insulin-dependent diabetes mellitus (NIDDM). A 2002 study ~onducted by Ciardullo et 
al., found that the prevalence of diabetes in the general population of Italy was estimated 
to be 3-4% and increasing with age. Of all diabetes patients, 90% have T2DM, which 
presents in adulthood. In Sweden, the prevalence of DM is about 3-4% of the total 
population. Although the current absolute numbers are unknown, it is estimated that 
about 300,000 Swedish suffer from the disease, which may be a conservative estimate 
because of the rapid increase in T2DM prevalence (Henriksson and Jonsson, 1998; King 
et al., 1998). 
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A number of epidemiological studies have been carried out since the early 1960s to 
explain the prevalence and nature of diabetes in African populations. The prevalence of 
DM in Africa has paralleled the sharply rising international trends (Motala, 2002). The 
majority of patients in African countries who suffer from diabetes are between the ages 
of 45 and 64, which is similar to other developing countries (Wild et al., 2004). About 
70-90% of African diabetic patients have T2DM and 25% have TIDM (Abdelgadir, 
2006). The reported prevalence of T2DM among the adult population in Northern Sudan 
is 10.4%, while the prevalence of TlDM in all ages ranges from 0.3/1000 in Nigeria to 
0.9511000 in Sudan (Motala et al., 2003). 
There are no studies to reflect the current situation of DM in the Eastern 
Mediterranean/Middle East region, because not all countries have data from nationwide 
health surveys. However, consistent with global trends, it is estimated that these 
countries will also experience a rapid increase in the rates of obesity and diabetes. In 
these regions, majority of health problems arise because of inconsistent levels of care 
between rural and urban centres as well as emphasis on treatment instead of prevention 
(Bouguerra eta!., 2007). 
The Asia-Pacific region (APR) represents the most important reg10n for any 
epidemiological study of diabetes, as it is the most populated area of the world. Its 
largest country, China, contains 20% of the world population (1.2 billion), followed by 
India with its population of 1 billion, and Indonesia with a. population of about 200 
million people. The combined population of this region is extremely high and has been 
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experiencing a rapidly rising prevalence of diabetes (Cockram, 2000). For example, in 
1998 it was estimated that approximately 140 million people suffered from diabetes, 
throughout the world (Cockram, 2000). The WHO predicts that this figure will rise to 
300 million people by the year 2025, with more than 150 million of these patients 
residing in Asia, 90 million of whom will be in China and India (Yoon et al., 2006). 
Another study (Gimeno eta!., 2002) reported that the prevalence ofDM has worsened in 
Japanese-Brazilians over the past 7 years such that they have one of the highest 
prevalence rates in the world. The recent Australian Diabetes, Obesity and Lifestyle 
Study (AusDiab) conducted in 2002 by Hilton et al., found that 7.5% of the Australian 
population aged 25 years and older suffered from T2DM. Over 90% of undiagnosed 
Australian diabetes patients had recognizable risk factor during their visit to the general 
practitioners (GPs) each year. Therefore, the Australian GPS identified about 300,000 to 
500,000 Australians suffer from undiagnosed diabetes. This study concluded that early 
diagnosis is a major factor for minimizing the .risk of micro- and macrovascular 
complications. 
1.1.2 Prevalence in Malaysia 
A study published in 2000 by Zaini concluded that Malaysians were living an improved 
life expectancy, yet sedentary lifestyle with high intake of carbohydrates and fatty foods 
because of improved socio-economic conditions and stress. This trend represents 
multiple risk factors that will undoubtedly lead the Malaysian population into a diabetes 
epidemic. The estimated number of adults with DM in Malaysia in 2000 was 940,000, a 
figure that is expected to rise to 2.48 million people by 2030 (Cruez, 2008). According 
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to 2008 Ministry of Health Malaysia statistics, Malaysia has a population of just over 
25,000,000 people; thus, nearly 17% of the general population of Malaysia suffers from 
DM~ 
The recently published Third National Health and Morbidity Survey of 2006 (NHM 3) 
found that the prevalence of the most common chronic diseases in Malaysia had 
increased compared to the last survey in 1996. The prevalence of DM was found to have 
increased from 8.3% to 14.9%, and the prevalence of HPT was increased to 43% from 
33% (Rashid, 2008). 
1.3 Diagnosis of diabetes mellitus 
The 1999 Malaysian Consensus (MC) practice guidelines for Type 2 Diabetes mellitus 
(T2DM) management 2"d edition, recommend that any individual who displays 
symptoms such as weight loss, tiredness, lethargy, polyuria, polyphagia, polydipsia, 
pruritus vulvae and banalities be screened for DM. Moreover, individuals who present to 
a primary health care facility for any reason with any of the following characteristics 
should be screened for diabetes, regardless of whether they display symptoms: aged 35 
years and over, obesity (BMI ~ 30), history of gestational DM, history of big baby (birth 
~ 4.0 kg.), family history of diabetes, hypertension and hyperlipidaemia, (total 
cholesterol > 6.5 m mol/1 and fasting triglyceride > 2.3 m mol/1). All pregnant women 
should be screened at least once at ~ 24/52 period of gestation. 
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If the symptoms of a patient are suspicious for diabetes, urine and blood glucose tests are 
used to confirm the diagnosis (Cutler, 2003). The presence of ketones and protein in the 
urine helps diagnose diabetes and evaluate kidney function. However, a study by 
Kuzuya et a!., in 2002 reported that the diagnoses of diabetes and pre-diabetes are done 
definitively by measuring BG or fasting plasma glucose (FPG) levels. Individual with 
either a borderline or normal FPG level that present with some symptoms of diabetes 
may require an oral glucose tolerance test (OGTT) to confirm the diagnosis of diabetes 
(Kuzuya eta!., 2002). OGTT is a special test that measures the ability of the body to 
utilize glucose. 
Several different criteria exist for the diagnosis of hyperglycaemia and diabetes based on 
FPG and OGTT results. These criteria include the 1997 American Diabetes Association 
(ADA) criteria as well as the 1985 and 1999 WHO criteria (Gahir et al., 2000). In the 
1985 WHO criteria, diabetes could be diagnosed by either a fasting plasma .glucose 
(FPG) ~ 7.8 mmol/1 (140 mg/dl) or a 2-hour post load plasma glucose (2-h PG) ~ 11.1 
mmol/1 (~ 200 mg/dl) after a 75-g OGTT load (Gabir eta!., 2000), while the ADA 1997, 
criteria stated that both TIDM and T2DM could be confirmed by a FPG level ~7.0 
mmol/l (~ 125 mg/dl) on two separate occasions {Gahir et al., 2000; the US Expert 
Committee Report, 2002). On the other hand, the WHO 1999 criteria recommends an 
OGTT if the FPG is~ 7.0 mmol/l, and states that the diagnosis of diabetes is confirmed if 
the 2-h PG is~ 11.1 mmol (V accacro et al., 1999; Lindstrom et al., 2003). 
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1.4 Management of diabetes mellitus 
Management of diabetes is designed to maintain BG levels within a normal range, termed 
euglycaemia. Currently, there is no cure for diabetes (Halban, 2006); however, 
appropriate management of patients with .DM will help delay the progression of the 
disease, reduce the development of its complications, and improve clinical outcomes 
(Wyne and Bell, 2004). TlDM patients require regular injection of insulin to adjust BG 
levels, as their bodies cannot produce enough insulin. The first line for T2DM 
management is diet modification and exercise. If these manoeuvres fail to control BG, 
an oral hypoglycaemic agent (OHA) could be added. A 2002 study by Assai et al., stated 
that regular blood glucose monitoring, medication compliance and careful self-
management of the disease are important to stabilize blood glucose levels and eliminate 
the symptoms of hyperglycaemia. Hence, proper T2DM management is important in 
order to achieve the long-term goals of treatment, which are prolonged life, symptom 
relief and prevention of long-term DM complications such as heart disease and kidney 
failure. 
1.4.1 Non-drug therapies 
The most important non-drug therapy is behaviour modification for a healthier life-style. 
Diabetic patients are encouraged to modify their daily diet such that it is well balanced, 
and to perform regular exercise(Franz et al., 2002). 
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1.4.1 (a) Dietary therapy 
Nutritional recommendations for diabetic patients are the same as for non-diabetic 
individuals. A 2007 study by Dedoussis reported that diet management is a main factor 
for maintaining long-term health and quality of life for people with T2DM. General 
. 
intake guidelines include 50-60% of daily energy requirements deriyed from 
carbohydrates, low glycaemic index foods, foods containing cereal fibre and a protein 
intake of least 0.86 glkg/day. The consumption of added sugars can be up to 10% of 
daily energy requirements. Also, guidelines recommend a limited intake of total fat, 
especially saturated fats and monounsaturated fatty acids (MUFA) where possible, 
appropriate use of nutritive and non-nutritive sweeteners, and a daily vitamin and mineral 
supplement. 
1.4.1 (b) Exercise 
Increased physical activity and regular exercise is an important element of diabetes 
management. Exercising muscles require more glucose to meet their energy 
requirements, and therefore regular exercise removes excessive sugar from the body and 
improves insulin sensitivity (Quesada, 2003). Though a healthy, nutritious diet and a 
moderate exercise regimen represent the foundations of T2DM management, weight loss 
is another important tool for diabetes control (Flood, 2007). Therefore, patients with 
mild to moderate disease may initially utilize diet and exercise alone to restore effective 
glycaemic control. 
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1.4.2 Drug therapies 
As diabetes progresses, the pharmacologic interventions are required to achieve 
euglycaemia. The choice for first line drug therapy depends on the type of diabetes. 
Exogenous insulin is needed for Tl DM, while in T2DM different classes of oral 
hypoglycaemic agents (OHAs) are used. A 1999 study by Damsbo et al., and a 2007 
study by Modi both stated that OHAs have variable mechanisms by which they 
normalize BG. These include either promoting insulin secretion by the pancreas, 
increasing insulin sensitivity or delaying the rate at which glucose is absorbed from the 
gastrointestinal tract (GIT). Insulin may be required for T2DM therapy if a patient does 
\ 
not attain glycaemic goals by oral therapy. 
1.4.2 (a) Oral hypoglycaemic agents (OHA) 
There are five classes of oral hypoglycaemic agents (OHAs) approved for the treatment 
of T2DM. These drugs vary in their mechanism and site of action as well as their 
duration of action and reduction in HbAlc levels. These OHAs include sulfonylureas 
and meglitinides, which are also known as secretagogues, biguanides and 
thiazolidinediones, which are also known as_sensitizers, and alpha-glucosidase inhibitors, 
which help to delay the absorption of carbohydrates in the GIT (Deng et al., 2007). 
The ability of an OHA to reduce BG levels varies depending on the aetiology of the 
diabetes. A non-obese patient usually receives sulfonylureas as first line therapy, 
whereas an obese patient usually responds better to metformin (biguanides). A 
combination of OHAs is used if one OHA is insufficient to ~ontrol BG effectively. 
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Some patients may even need a combination of more than two drugs to maintain 
euglycaemia. 
(ii) Sulfonylureas 
Sulfonylureas have been used as first-line oral anti-hyperglycaemic agents for T2DM 
since 1954 (V agula and Devi, 2008). Historically, sulfonylureas have been most widely 
used to start oral drug therapy for non-obese T2DM patients, while metformin has been 
preferred for obese patients (Baily and Day, 2003). Sulfonylureas are thought stimulate 
insulin release from the beta cells of pancreatic islets by inhibition of potassium sensitive 
adenosine triphosphate (ATP) channels (KATP channels) in the ~-cell membrane. When 
" 
sulfonylureas bind to their receptors, they presumably close the KATP channels, which 
lead to a decrease in the K+ permeability of the ~-cell membrane. This change 
depolarizes the cell, triggering a calcium influx that activates the insulin secretion 
machinery. Sulfonylureas also promote insulin exocytosis by direct interaction with the 
secretory machinery, without closing the plasma membrane KATP channels. This effect is 
dependent on protein kinase C (PKC), and was observed at therapeutic concentrations of 
sulfonylureas, which properly contributes to their hypoglycaemic action in diabetics 
(Eliassen et al., 1996; Geng et al., 2007). Sulfonylureas are classified into first-
generation and second-generation compounds. They vary in their potency, safety, and 
pharmacokinetic characteristics. The second-generation agents, including glipizide 
(Minidiab, Glucotrol <R>), glibenclamide, known as glyburide in USA, (Daonil, Diabeta, 
Micronase, Glynase <R>), gliclazide (Diamicron<R>), and glimepiride (Amaryl<R>), are 
characterized by their high potency as well as improved pharmacokinetic and safety 
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profiles (Modi, 2007). The first-generation sulfonylureas include acetohexamide 
(Dymelor<R>), tolbutamide (Rastinon, OrinaseCR>), tolazamide (TolinaseCR>) and 
chlorpropamide (Diabinese<R>). Chlorpropamide and tolbutamide are the most commonly 
utilized first generation sulfonylureas. A 2007 study from Meyer and DalPan and a 2005 
study from Bastaki stated that the choice of sulfonylurea depends on the propensity of 
the patient to develop hypoglycaemia as a result of different pharmacokinetics, since the 
long-acting sulfonylureas can induce hypoglycaemia while the short-acting agents may 
not cause euglycaemia. 
Sulfonylureas are generally taken one to two times a day, before meals. Their dosing 
schedule is included in (Appendix C). They are well tolerated and have a low incidence 
of side effects. The most common sulfonylurea side effect is hypoglycaemia, which can 
occur due to an unnecessarily high dose, excessive physical activity or improper diet. 
Hypoglycaemia manifests as hunger, nausea/vomiting, fatigue, headache, tremor, finger 
tingling, mouth numbness and muscle weakness (Inzucchi et a/., 2005). Furthermore, 
sulfonylureas are contraindicated in TIDM, people with sulfa allergies, and patients with 
advanced liver or kidney disease. Sulfonylureas are not recommended in pregnancy due 
to the studies that showed adverse effects on animal foetuses. There are no adequate 
studies regarding the effects of sulfonylureas on the human foetus. It is also important to 
note that second generations sulfonylureas have less drug-drug interactions than first 
generation compounds. 
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(ii) Meglitinides 
These agents enhance insulin release from the pancreas over a short period of time only 
if blood glucose levels are high. Therefore, they are classified as short-acting 
secretagogues (Lewis, 2002). Meglitinides first became available in 1997 for the 
treatment of T2DM patientso Their brand names are Prandin(R) (repaglinide) and 
Starlix<R>, and they are taken orally two to four times per day with mealso As for side 
effects, they have a low risk ofhypoglycaemia, but may cause weight gaino 
{iii) Biguanides 
Biguanides, (metformin, phenformin and buformin) reduce hepatic glucose output and 
stimulate the transportation of glucose into muscle in the presence of insulino This class 
of drugs is ineffective for non-insulin dependent (NIDDM) treatment (Modi, 2007). 
Biguanides must be used with caution in patients with impaired liver or kidney function. 
Metformin hydrochloride is one of the most commonly used first-line oral agents for the 
treatment of T2DM (Bastaki, 2005). Metformin lowers blood glucose levels primarily 
by decreasing the amount of glucose produced by the liver. It also helps to lower blood 
glucose levels by improving the sensitivity to insulin, such that glucose can be absorbed. 
The usual starting dose of metformin hydrochloride tablets is 500 mg twice a day or 850 
mg once a day, given with meals. Dosage increases should be made in increments of500 
mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided 
doses. Metformin as a monotherapy is usually not accompanied by hypoglycaemia, and 
has been used safely in patients with pre-diabetic hyperglycaemia (Nathan, eta!., 2006). 
22 
The major non-glycaemic effect of metformin is either weight stability or modest weight 
loss, which is in contrast to many of the other blood glucose-lowering medications that 
can cause weight gain. The common side effects of metformin include nausea and 
diarrhoea, but these are improved over time when taken with food. 
(iv) Thiazolidinediones 
Thiazolidinediones (TZDs, also known as glitazones) are insulin sensitizers now widely 
used for the treatment of T2DM. Three TZDs have been used in clinical practice, 
namely troglitazone, pioglitazone, and rosiglitazone (V agula and Devi, 2008). TZDs 
have been used to treat T2DM since the late 1990s and the normal dose is once or twice 
daily. 
<Jlitazones can be useful in patients who are at high risk of cardiovascular disease, as 
they have been demonstrated to improve patient lipid profiles (Nass and Blumenthal, 
2000; Black, 2003; Wilding, 2006). Common side effects of TZDs include upper 
respiratory infections, sinus infections, headaches and mild anaemia. Serious side effects 
include fluid retention, heart failure, muscle pain and weight gain. 
(v) Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors {acarbose, miglitol and voglibose) delay digestion and 
absorption of carbohydrates at the intestinal lining (Krentz and Baily, 2005). They may 
be used as monotherapy in conjunction with an appropriate diabetic diet and exercise or 
as adjunctive therapies with other anti-diabetic drugs for T2DM. Acarbose is the most 
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commonly used drug in this class. Side effects of this drug class include episodes of 
hypoglycaemia and gastrointestinal disturbances such as flatulence and diarrhoea. 
1.4.2 (b) Insulin 
Insulin is a hormone produced by the P-cells of pancreas that is released into the portal 
vein and reaches peripheral circulation. It is considered as one of the most potent 
regulators of blood glucose level, in addition to, its extensive effects on both metabolism 
and several other body systems (e.g., vascular compliance). Insulin increases glucose 
utilization b~ cells in the_Jiver~ muscle and fat tissue by converting excess glucose to 
glycogen for storage in the liver and muscle. Insulin also inhibits the catabolism of fat 
and amino acids (AA) for energy production (Yang, 2004). A deficiency or absence of 
insulin creates a defect in the insulin central metabolic control mechanism (transfer of 
lipids from adipose tissue to the liver for mobilization as an energy source), a defect in its 
status as control signal to other body systems (such as amino acid uptake by body cells) 
and a defect in the anabolic effects throughout the body. Hence, a decrease in the amount 
of insulin released results in DM. (Turner eta!., 1999). 
The amount and type of insulin required depends on the height, weight, age, food intake, 
and activity level of a diabetic patient (Vagula and Devi, 2008). Some patients with 
T2DM may also need to use insulin injections if their diabetes cannot be controlled with 
diet, exercise, and oral medication. Insulin, derived from the pancreas of animals, was 
first available for diabetic patients in the 1920s. This extracted insulin would vary with 
the animal species it was obtained from, such as cows and pigs. Recently, the genetically 
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